Abstract: Past four decades have seen a concerted push to develop regenerative treatments for incurable neurodegenerative diseases such as Parkinson’s disease (PD). PD’s pathophysiology is primarily characterized by dopamine deficiency caused by the progressive depletion of neurons in substantia nigra (Bernheimer et al., 1973). So, it is not very surprising that most attempts at regenerative treatment of PD focus on using pre-differentiated, dopaminergic neurons. However, PD’s pathogenesis spans far beyond strictly dopamine deficiency and is still not completely known (Chaudhuri et al., 2006). Thus, attempts at implanting pre-differentiated dopaminergic neurons that are locked into a single, inflexible function, predictably ran into the same problems as dopamine replacement therapy: 1) These cells are not curative; 2) They cannot address all PD deficits, and 3) They tend to cause side effects (Kordower et al., 2017). In order to address the multifactorial nature of this disease, we suggest the use of non-tumorigenic undifferentiated stem cells. Unlike adult cells, undifferentiated cells, due to their inherent plasticity, have the potential to respond to microenvironmental cues (Martínez-Cerdeño et al., 2017) from the Parkinsonian brain, target multiple systems and pathways, and eventually restore both structure and function (Figure 1).